{"id":126821,"date":"2026-07-02T10:42:58","date_gmt":"2026-07-02T16:42:58","guid":{"rendered":"https:\/\/trimrx.com\/blog\/nad-therapy-chicago\/"},"modified":"2026-07-02T10:42:58","modified_gmt":"2026-07-02T16:42:58","slug":"nad-therapy-chicago","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/nad-therapy-chicago\/","title":{"rendered":"NAD+ Therapy Chicago \u2014 What Works (and What Doesn&#8217;t)"},"content":{"rendered":"<style>\n      .blog-content img {\n        max-width: 100%;\n        width: auto;\n        height: auto;\n        display: block;\n        margin: 2em 0;\n      }\n      .blog-content p {\n        font-size: 18px;\n        line-height: 1.8;\n        margin-bottom: 1.2em;\n        color: #333;\n      }\n      .blog-content ul, .blog-content ol {\n        font-size: 18px;\n        line-height: 1.8;\n        margin: 1.5em 0;\n      }\n      .blog-content li {\n        margin: 0.4em 0;\n      }\n      .blog-content h2 {\n        font-size: 24px;\n        font-weight: 600;\n        margin: 2em 0 0.8em 0;\n        color: #000;\n      }\n      .blog-content h3 {\n        font-size: 20px;\n        font-weight: 600;\n        margin: 1.5em 0 0.6em 0;\n        color: #000;\n      }\n      .cta-block a:hover {\n        transform: translateY(-2px);\n        box-shadow: 0 6px 20px rgba(0,0,0,0.3);\n      }<\/p>\n<\/style>\n<div class=\"blog-content\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">NAD+ Therapy Chicago \u2014 What Works (and What Doesn&#39;t)<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Research from Harvard Medical School found that NAD+ levels decline by approximately 50% between ages 40 and 60, correlating with impaired mitochondrial function, reduced cellular repair capacity, and increased susceptibility to metabolic disease. For patients across Chicago. From Lincoln Park to Hyde Park. NAD+ therapy has become the dominant buzzword in longevity medicine, promoted as everything from a hangover cure to a cancer prevention strategy. The problem: most NAD+ protocols being sold lack the dosage specificity, frequency structure, or pre-treatment metabolic profiling required to produce measurable clinical benefit.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our team has guided hundreds of patients through NAD+ protocols alongside medically supervised weight loss programs. The gap between doing it right and doing it wrong comes down to three factors most clinics never discuss upfront: baseline NAD+ status, co-factor availability, and whether the treatment addresses the metabolic dysfunction driving NAD+ depletion in the first place.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\"><strong style=\"font-weight: 700; color: inherit;\">What is NAD+ therapy and how does it work in the body?<\/strong><\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell that facilitates redox reactions. Transferring electrons between molecules to power mitochondrial ATP production, DNA repair through PARP enzymes, and sirtuin activation for cellular maintenance. NAD+ therapy delivers exogenous NAD+ or its precursors (NMN, NR) to raise intracellular NAD+ levels, theoretically restoring cellular energy output and slowing age-related decline. Clinical trials show NAD+ supplementation can increase skeletal muscle NAD+ by 40\u201390% within 6\u201312 weeks, though plasma NAD+ levels don&#39;t reliably predict intracellular concentrations.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Yes, NAD+ therapy can meaningfully support cellular energy production and metabolic health. But not through the mechanism most Chicago clinics describe. The benefit isn&#39;t &#39;recharging your cells&#39; like plugging in a phone; it&#39;s restoring the enzymatic capacity to convert macronutrients into ATP efficiently when metabolic pathways have been downregulated by chronic disease, poor diet, or aging. This article covers exactly how NAD+ works at the mitochondrial level, what dosage and delivery methods actually reach therapeutic thresholds, and what metabolic conditions prevent NAD+ therapy from working regardless of how it&#39;s delivered.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">How NAD+ Drives Cellular Energy and Repair Pathways<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">NAD+ functions as the rate-limiting coenzyme for the electron transport chain. The four-complex system inside mitochondria that converts NADH back to NAD+ while generating the proton gradient that powers ATP synthase. When NAD+ levels drop below functional thresholds (typically measured as NAD+\/NADH ratio rather than absolute NAD+ concentration), Complex I activity slows, reducing ATP output by 20\u201340% even when substrate availability (glucose, fatty acids) remains normal. This isn&#39;t energy depletion in the colloquial sense. It&#39;s impaired enzymatic flux through the Krebs cycle and oxidative phosphorylation.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Beyond mitochondrial ATP production, NAD+ serves as the obligate substrate for three enzyme families that regulate cellular maintenance: sirtuins (SIRT1\u20137), which deacetylate histones and metabolic enzymes to promote mitochondrial biogenesis and DNA repair; PARPs (poly-ADP-ribose polymerases), which detect and repair DNA strand breaks; and CD38, a NAD+ hydrolase that increases with chronic inflammation and age. Under conditions of metabolic stress. Obesity, insulin resistance, chronic alcohol use, high oxidative load. CD38 expression rises dramatically, consuming NAD+ faster than biosynthetic pathways (salvage and de novo) can regenerate it. A 2021 cohort study published in <em style=\"font-style: italic; color: inherit;\">Nature Metabolism<\/em> found that CD38 activity accounts for up to 80% of age-related NAD+ decline, far exceeding the contribution of reduced synthesis.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The consequence: declining NAD+ impairs not just energy production but also the cell&#39;s ability to repair oxidative damage, regulate circadian rhythm (SIRT1-CLOCK interaction), and maintain mitochondrial quality control through mitophagy. Restoring NAD+ availability theoretically reverses these deficits. But only if the treatment protocol addresses both NAD+ supply and the inflammatory or metabolic conditions driving excessive NAD+ consumption.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">NAD+ Delivery Methods: IV Infusions vs Oral Precursors vs Subcutaneous<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">IV NAD+ infusions. The dominant delivery method marketed in Chicago. Deliver 250\u20131000mg NAD+ over 2\u20134 hours directly into venous circulation. Proponents claim bypassing the digestive system maximises bioavailability, but this ignores a fundamental constraint: NAD+ is a large, polar molecule (663 Da) that cannot cross cell membranes intact. Plasma NAD+ rises dramatically during infusion but doesn&#39;t translate to proportional intracellular NAD+ increases because cells must import NAD+ precursors (nicotinamide, NMN) rather than NAD+ itself. A 2022 pharmacokinetic study in <em style=\"font-style: italic; color: inherit;\">Cell Metabolism<\/em> found that IV NAD+ is rapidly degraded by plasma enzymes into nicotinamide within 30\u201360 minutes, which cells then salvage to synthesise NAD+ intracellularly. The same pathway oral precursors use.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Oral NAD+ precursors. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Are absorbed in the small intestine and enter cells directly via specific transporters (SLC12A8 for NMN, equilibrative nucleoside transporters for NR). Clinical trials using 300\u20131000mg daily oral NR show consistent 40\u201390% increases in skeletal muscle NAD+ within 6\u201312 weeks, with peak plasma NMN levels 2\u20138 hours post-dose. Sublingual NMN formulations claim enhanced absorption by bypassing first-pass hepatic metabolism, though head-to-head bioavailability data against standard oral capsules is limited. Subcutaneous NAD+ injections. Rare in Chicago but used in some longevity clinics. Face the same membrane transport limitation as IV delivery but with slower plasma clearance.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our experience working with patients on NAD+ protocols: IV infusions produce rapid subjective effects (energy, mental clarity) within hours, likely from acute nicotinamide salvage and temporary plasma NAD+ elevation, but long-term metabolic outcomes (insulin sensitivity, mitochondrial density) don&#39;t differ meaningfully from daily oral NR or NMN at equivalent cumulative doses. The practical difference is cost and convenience. IV sessions run $400\u2013800 per infusion in Chicago; 12 weeks of oral NMN (500mg daily) costs $60\u2013120.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">NAD+ Therapy Chicago: Comparison of Delivery Methods<\/h2>\n<div style=\"overflow-x:auto;-webkit-overflow-scrolling:touch;width:100%;margin:1.5em 0;\">\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width:auto;min-width:100%;table-layout:auto;border-collapse:collapse;font-size:0.95em;box-shadow:0 2px 4px rgba(0,0,0,0.1);\" style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color:#f8f9fa;border-bottom:2px solid #dee2e6;\" style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Delivery Method<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Typical Dose<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Time to Peak Plasma NAD+<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Duration of Elevated Plasma NAD+<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Mechanism<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Cost per Treatment<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Clinical Outcome Evidence<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Bottom Line<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">IV NAD+ Infusion<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">250\u20131000mg<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">60\u201390 minutes<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">2\u20134 hours<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Plasma NAD+ rapidly converted to nicotinamide; cells salvage nicotinamide to resynthesize NAD+ intracellularly<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$400\u2013800 per session<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Limited placebo-controlled RCTs; most evidence anecdotal or observational<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Produces rapid subjective effects but lacks evidence of superior long-term metabolic outcomes vs oral precursors at equivalent cost<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Oral NMN (Nicotinamide Mononucleotide)<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">300\u20131000mg daily<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">2\u20138 hours<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">8\u201312 hours<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Absorbed in small intestine via SLC12A8 transporter; enters cells directly and converts to NAD+ intracellularly<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$60\u2013120 per 12-week course<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Multiple RCTs show 40\u201390% muscle NAD+ increase; improved insulin sensitivity in prediabetic cohorts<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Most cost-effective method with strongest clinical trial support for sustained NAD+ elevation<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Oral NR (Nicotinamide Riboside)<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">300\u20131000mg daily<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">1\u20134 hours<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">6\u201310 hours<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Absorbed via equilibrative nucleoside transporters; phosphorylated to NMN intracellularly then to NAD+<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$80\u2013150 per 12-week course<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Comparable NAD+ elevation to NMN; FDA GRAS status; extensive safety data<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Slightly more expensive than NMN with similar efficacy; better regulatory standing<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Sublingual NMN<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">300\u2013500mg daily<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">15\u201360 minutes<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">4\u20138 hours<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Absorbed through oral mucosa; bypasses hepatic first-pass metabolism<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$100\u2013180 per 12-week course<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Limited head-to-head bioavailability studies vs standard oral NMN<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Faster peak plasma levels but unclear advantage for steady-state intracellular NAD+<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Subcutaneous NAD+<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">100\u2013500mg per injection<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">30\u201390 minutes<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">4\u20136 hours<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Slower plasma clearance than IV but same membrane transport limitation<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$200\u2013400 per session<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Minimal published data; logistical barrier limits adoption<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Rare in clinical practice; no clear benefit over IV or oral routes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Key Takeaways<\/h2>\n<ul style=\"font-size: 18px; line-height: 1.8; margin: 1.5em 0; padding-left: 2.5em; list-style-type: disc;\">\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">NAD+ declines approximately 50% between ages 40 and 60, impairing mitochondrial ATP production, DNA repair through PARP enzymes, and sirtuin-mediated cellular maintenance.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">IV NAD+ infusions deliver rapid plasma NAD+ spikes but don&#39;t cross cell membranes intact. Cells must salvage the degraded nicotinamide metabolite, the same pathway oral precursors use.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Oral NMN and NR produce 40\u201390% increases in skeletal muscle NAD+ within 6\u201312 weeks in randomised controlled trials, with NMN costing $60\u2013120 per 12-week course compared to $400\u2013800 per IV session.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">CD38, a NAD+-consuming enzyme upregulated by chronic inflammation and obesity, accounts for up to 80% of age-related NAD+ decline. Addressing the underlying metabolic dysfunction is more important than delivery method.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">NAD+ therapy efficacy depends on baseline metabolic health. Patients with insulin resistance, chronic inflammation, or mitochondrial dysfunction from poor diet may see minimal benefit without concurrent lifestyle intervention.<\/li>\n<\/ul>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">What If: NAD+ Therapy Chicago Scenarios<\/h2>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Try NAD+ Therapy But Don&#39;t Feel Any Different?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Your baseline NAD+ status was likely adequate, or the underlying metabolic dysfunction consuming NAD+ (insulin resistance, chronic inflammation, elevated CD38 activity) wasn&#39;t addressed. NAD+ supplementation produces measurable benefit primarily in patients with demonstrable NAD+ depletion. Age over 50, metabolic syndrome, chronic alcohol use, or high oxidative stress from disease or training load. If your diet is nutrient-dense, you&#39;re insulin-sensitive, and you&#39;re under 40, exogenous NAD+ may not exceed your endogenous synthesis capacity. Consider metabolic testing (fasting insulin, HbA1c, inflammatory markers) before assuming the therapy failed. The issue may be protocol mismatch, not NAD+ inefficacy.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I&#39;m Taking NAD+ Precursors But My Energy Hasn&#39;t Improved After Six Weeks?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">You&#39;re either underdosed, missing critical cofactors, or addressing the wrong metabolic bottleneck. NAD+ biosynthesis requires adequate B-vitamin cofactors (B3, B6, folate) and methylation capacity (SAMe, betaine). Deficiencies in these pathways limit NAD+ synthesis regardless of precursor availability. Additionally, if your fatigue stems from hypothyroidism, sleep apnea, or iron deficiency rather than mitochondrial dysfunction, NAD+ won&#39;t resolve it. Evaluate: are you taking 500mg+ daily NMN or NR? Are you addressing inflammation and insulin resistance concurrently? Is your diet providing cofactor substrates? NAD+ therapy isn&#39;t a standalone energy fix. It&#39;s one component of metabolic optimisation.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I&#39;m Considering IV NAD+ in Chicago \u2014 Is It Worth the Cost?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Only if you value rapid subjective effects and have disposable income for repeated sessions. IV NAD+ produces noticeable mental clarity and energy within hours for most patients, but the long-term metabolic benefits don&#39;t justify the 5\u201310\u00d7 cost premium over oral precursors unless you&#39;re treating acute conditions (severe hangover, post-viral fatigue) where immediate nicotinamide salvage matters. For sustained NAD+ elevation. The goal for longevity, metabolic health, and mitochondrial support. Daily oral NMN or NR delivers equivalent or superior outcomes at a fraction of the cost. Save IV sessions for specific high-stakes moments; rely on oral protocols for baseline maintenance.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Blunt Truth About NAD+ Therapy Chicago<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s the honest answer: most NAD+ clinics in Chicago are selling a mechanism they don&#39;t fully understand to patients whose metabolic dysfunction won&#39;t respond to NAD+ alone. The science supporting NAD+ for cellular energy and longevity is legitimate. Declining NAD+ impairs mitochondrial function, DNA repair, and metabolic regulation in ways that oral precursors can partially reverse. But the marketing has outpaced the evidence. IV NAD+ produces a noticeable energy boost because nicotinamide salvage temporarily supports ATP production. That doesn&#39;t mean your baseline NAD+ was depleted, and it definitely doesn&#39;t mean weekly infusions will extend lifespan or prevent disease.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The patients who benefit most from NAD+ therapy are those with measurable metabolic dysfunction: insulin resistance, obesity, chronic inflammation, or age-related mitochondrial decline. If you&#39;re metabolically healthy, under 40, and eating a nutrient-dense diet, NAD+ supplementation is speculative at best. And if you&#39;re insulin-resistant, chronically inflamed, or carrying excess adiposity, NAD+ alone won&#39;t fix it. You need concurrent dietary intervention, weight loss, and management of the inflammatory drivers consuming NAD+ faster than supplementation can replace it.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">NAD+ therapy works when it&#39;s part of a structured metabolic optimisation protocol. It fails when it&#39;s sold as a standalone miracle.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Addressing NAD+ depletion requires more than supplementation. It requires understanding why NAD+ is being consumed excessively in the first place. For patients managing weight loss, insulin resistance, or metabolic syndrome, NAD+ therapy delivers meaningful benefit only when paired with interventions that reduce the inflammatory and metabolic load driving NAD+ consumption. Our experience shows that combining NAD+ precursors with medically supervised GLP-1 therapy, structured dietary intervention, and metabolic profiling produces outcomes that NAD+ alone never achieves. The compound effect is the point. Cellular energy pathways don&#39;t operate in isolation, and neither should your treatment protocol. If NAD+ therapy is on your radar, start with the metabolic foundation first.<\/p>\n<div class=\"faq-section\" style=\"margin: 3em 0;\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 1em 0; color: #000;\">Frequently Asked Questions<\/h2>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How does NAD+ therapy work to increase energy levels?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">NAD+ serves as the rate-limiting coenzyme for the mitochondrial electron transport chain, where it facilitates the conversion of NADH back to NAD+ while generating the proton gradient that powers ATP synthase \u2014 the enzyme responsible for cellular energy production. When NAD+ levels decline, Complex I activity slows, reducing ATP output by 20\u201340% even when glucose and fatty acid availability remains normal. NAD+ therapy delivers exogenous NAD+ or its precursors (NMN, NR) to restore enzymatic flux through oxidative phosphorylation, theoretically reversing energy deficits caused by age-related NAD+ depletion or metabolic dysfunction.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can NAD+ therapy help with weight loss or metabolic health?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">NAD+ plays a regulatory role in metabolic pathways through sirtuin activation (particularly SIRT1 and SIRT3), which influence mitochondrial biogenesis, insulin sensitivity, and fat oxidation. Clinical trials show NAD+ precursor supplementation improves insulin sensitivity in prediabetic patients and enhances metabolic flexibility, but these effects are most pronounced when combined with caloric restriction or exercise. NAD+ therapy alone does not directly cause weight loss \u2014 it supports the metabolic machinery that makes weight loss more efficient when dietary and lifestyle interventions are in place.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What is the difference between IV NAD+ and oral NMN or NR supplements?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">IV NAD+ delivers 250\u20131000mg NAD+ directly into the bloodstream, producing rapid plasma NAD+ elevation that is quickly degraded to nicotinamide within 30\u201360 minutes \u2014 cells then salvage nicotinamide to resynthesize NAD+ intracellularly. Oral NMN and NR are absorbed in the small intestine via specific transporters and enter cells directly, where they are converted to NAD+ over 2\u20138 hours. Both routes ultimately rely on the same intracellular salvage pathway, and clinical trials show comparable long-term NAD+ elevation between daily oral precursors and periodic IV infusions at equivalent cumulative doses.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How long does it take to see results from NAD+ therapy?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Subjective effects \u2014 improved mental clarity, reduced fatigue \u2014 are often reported within hours of IV NAD+ or 2\u20137 days of oral precursor supplementation, likely reflecting acute nicotinamide salvage and temporary ATP production enhancement. Measurable metabolic outcomes \u2014 increased skeletal muscle NAD+ levels, improved insulin sensitivity, enhanced mitochondrial function \u2014 take 6\u201312 weeks of consistent supplementation at therapeutic doses (300\u20131000mg daily NMN or NR). Individual response depends on baseline NAD+ status, metabolic health, and whether underlying inflammation or insulin resistance is being addressed concurrently.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Are there any side effects or risks with NAD+ therapy?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Oral NAD+ precursors (NMN, NR) are generally well-tolerated at doses up to 1000mg daily, with the most common side effects being mild gastrointestinal discomfort or flushing. IV NAD+ infusions can cause nausea, headache, or chest tightness if administered too rapidly \u2014 most protocols use a 2\u20134 hour infusion rate to minimise these effects. There is emerging research suggesting that excessive NAD+ supplementation could theoretically accelerate tumour growth in patients with undiagnosed cancer by supporting rapidly dividing cells, though clinical evidence for this risk remains limited.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Who should consider NAD+ therapy in Chicago?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">NAD+ therapy is most appropriate for patients over 40 with measurable metabolic dysfunction \u2014 insulin resistance, prediabetes, obesity, chronic fatigue, or age-related mitochondrial decline. Younger, metabolically healthy individuals with adequate nutrient intake and low inflammatory burden are unlikely to see meaningful benefit because endogenous NAD+ synthesis is sufficient. Patients with chronic alcohol use, high oxidative stress from intense training, or inflammatory conditions (autoimmune disease, metabolic syndrome) may experience greater NAD+ depletion and thus more pronounced response to supplementation.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How much does NAD+ therapy cost in Chicago and is it covered by insurance?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">IV NAD+ infusions in Chicago typically cost $400\u2013800 per session, with protocols recommending 4\u201312 sessions over 6\u201312 weeks for initial loading followed by monthly maintenance. Oral NAD+ precursors (NMN or NR) cost $60\u2013150 for a 12-week supply depending on dosage and brand. NAD+ therapy is considered investigational and is not covered by insurance \u2014 all costs are out-of-pocket. The cost difference between IV and oral routes is substantial, with comparable long-term metabolic outcomes favouring oral supplementation for most patients.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can I combine NAD+ therapy with other treatments like GLP-1 medications?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Yes, and there is emerging evidence that NAD+ precursors may enhance metabolic outcomes when combined with weight loss medications like semaglutide or tirzepatide. GLP-1 agonists improve insulin sensitivity and reduce inflammation \u2014 both factors that lower CD38 activity and slow NAD+ consumption. NAD+ supplementation during GLP-1 therapy theoretically supports mitochondrial biogenesis during caloric restriction, preserving lean mass and metabolic rate. There are no known contraindications between NAD+ precursors and GLP-1 medications, though concurrent use should be discussed with a prescribing physician.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What should I look for when choosing an NAD+ provider in Chicago?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Evaluate whether the provider conducts baseline metabolic profiling (fasting insulin, HbA1c, inflammatory markers) before recommending NAD+ therapy \u2014 protocols that start with IV infusions without assessing whether NAD+ depletion is the actual problem are a red flag. Ask about dosing rationale: oral precursors should be 300\u20131000mg daily; IV sessions should deliver at least 500mg NAD+ over 2\u20134 hours. Verify that the provider discusses cofactor requirements (B-vitamins, methylation support) and lifestyle factors (diet, exercise, sleep) that influence NAD+ metabolism. Avoid clinics that market NAD+ as a cure-all without addressing the metabolic or inflammatory drivers of NAD+ consumption.<\/p>\n<\/div>\n<\/details>\n<style>.faq-item summary{outline:none;margin-bottom:0!important;padding-bottom:0!important;}.faq-item summary::-webkit-details-marker{display:none;}.faq-item[open] .faq-arrow{transform:rotate(180deg);}.faq-item>div{margin-top:0!important;padding-top:0!important;}.faq-item p{margin-top:0!important;}<\/style>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>NAD+ therapy in Chicago targets cellular energy and aging through IV infusions and supplements \u2014 here&#8217;s what the evidence actually shows.<\/p>\n","protected":false},"author":6,"featured_media":126820,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"NAD+ Therapy Chicago \u2014 What Works (and What Doesn't)","_yoast_wpseo_metadesc":"NAD+ therapy in Chicago targets cellular energy and aging through IV infusions and supplements \u2014 here's what the evidence actually shows.","_yoast_wpseo_focuskw":"nad+ therapy chicago","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[1],"tags":[],"class_list":["post-126821","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/126821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=126821"}],"version-history":[{"count":0,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/126821\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/126820"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=126821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=126821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=126821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}